Butyrate-containing structured lipids inhibit RAC1 and epithelial-to-mesenchymal transition markers: a chemopreventive mechanism against hepatocarcinogenesis
However, our findings indicate that TIR co-treatment fails to ameliorate the cognitive deficits caused by DXN
That difference could improve patients quality of life by enabling them to perform day-to-day activities such as getting out of a chair more easily
Genetic toxicology testing (Ames test, chromosomal aberration assays, micronucleus testing) returned negative results
The compounds nephrotoxic properties limit its therapeutic usefulness
Common side effects include injection site reactions such as redness, swelling, or discomfort, temporary nausea, occasional headaches, and fatigue in some users